老年癌症患者中的放射性药物:实用考量,聚焦前列腺癌治疗——国际老年肿瘤学会工作组立场文件
国际老年肿瘤学会工作组发布立场文件,讨论放射性药物在老年癌症患者中的分子影像与治疗应用。分子影像因使用药理学无活性剂量,年龄与衰弱通常不重要;治疗性核素可能影响正常功能如骨髓抑制。以镭-223为例,其在去势抵抗性前列腺癌伴症状性骨转移患者中带来生存获益,老年患者使用需肿瘤科与核医学科密切协调、考虑骨髓储备及肾功能调整剂量。
要点
- 分子影像用放射性药物仅需药理学无活性剂量,年龄和衰弱通常不影响其应用。
- 治疗性核素可能影响正常功能如骨髓抑制,老年患者需考虑骨髓储备。
- 镭-223在去势抵抗性前列腺癌伴症状性骨转移患者中带来生存获益。
核心结论
- 放射性药物在老年癌症患者中的治疗应用受到的关注很少。
- 在老年前列腺癌患者中,与细胞毒和细胞抑制药物相比,放射性核素可能具有使用便捷和毒性相对较少的优势。
研究设计与样本
- 国际老年肿瘤学会工作组立场文件,基于文献综述与专家意见形成。
主要发现
- 分子影像使用放射性药物可视化肿瘤存在与范围并监测治疗反应,提供预后和预测信息,如通过PET/CT量化活跃肿瘤负荷。
- 治疗性放射性药物包括靶向癌细胞特定表位的抗体和肽类。
- 在治疗性骨靶向药物中,镭-223在去势抵抗性前列腺癌伴症状性骨转移患者中带来生存获益。
关键数值与推荐
- 分子影像使用药理学无活性剂量,年龄和潜在衰弱通常不重要。
- 治疗性核素可能影响正常身体功能如骨髓抑制,需考虑骨髓储备。
- 大多数放射性药物经肾清除,老年患者可能需要调整剂量。
- 与年轻患者相比,对辐射诱导第二癌症等长期不良反应的担忧较少甚至没有。
临床怎么用
- 使用放射性核素治疗时,需要肿瘤科与核医学科密切协调以确保安全有效使用。
- 需考虑骨髓储备;大多数放射性药物经肾清除,老年患者可能需要调整剂量。
- 医疗人员、照护者和更广泛环境的安全问题可通过现行预防措施管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular imaging using radiopharmaceuticals has a clear role in visualising the presence and extent of tumour at diagnosis and monitoring response to therapy. Such imaging provides prognostic and predictive information relevant to management, e.g. by quantifying active tumour mass using positron emission tomography/computed tomography (PET/CT). As these techniques require only pharmacologically inactive doses, age and potential frailty are generally not important. However, this may be different for therapy involving radionuclides because the radiation can impact normal bodily function (e.g. myelosuppression). Since the introduction of Iodine-131 as a targeted therapy in thyroid cancer, several radiopharmaceuticals have been widely used. These include antibodies and peptides targeting specific epitopes on cancer cells. Among therapeutic bone seeking agents, radium-223 (223Ra) stands out as it results in survival gains in patients with castration-resistant prostate cancer and symptomatic bone metastases. The therapeutic use of radiopharmaceuticals in elderly cancer patients specifically has received little attention. In elderly prostate cancer patients, there may be advantages in radionuclides' ease of use and relative lack of toxicity compared with cytotoxic and cytostatic drugs. When using radionuclide therapies, close coordination between oncology and nuclear medicine is needed to ensure safe and effective use. Bone marrow reserve has to be considered. As most radiopharmaceuticals are cleared renally, dose adjustment may be required in the elderly. However, compared with younger patients there is less, if any, concern about adverse long-term radiation effects such as radiation-induced second cancers. Issues regarding the safety of medical staff, care givers and the wider environment can be managed by current precautions.
引用
- Prior JO, Gillessen S, Wirth M, et al. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. Eur J Cancer. 2017. PMID: 28391026. doi:10.1016/j.ejca.2017.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。